Anaplastic Large Cell Lymphoma, ALK-Positive Clinical Trial
Official title:
Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
The study aims to evaluate the prognostic value on the complete metabolic response rate (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the Overall Survival (OS). - at diagnosis - after the first cycle of CHOEP (early evaluation) - at the end of treatment
ALK-positive anaplastic large cell (anaplastic large-cell lymphoma, ALCL) is a rare adult disease for which almost all published studies are retrospective. The overall survival (OS) at 5 years varies from 70 to 87%. A recent international pooled analysis showed that the International Prognostic Index (IPI) had good predictive value for the PFS and the OS. In children, new prognostic factors have been identified: the titre of circulating anti-ALK antibodies (inverse correlation between the antibody titre and the prognosis), the detection of a NPM-ALK transcript in the blood at diagnosis (minimal disseminated disease, MDD); correlation between MDD positivity and pejorative prognosis) and its minimal residual disease (MRD), and the histological subtype (common versus small cells / lymphohistiocytic). The predictive value of the oncogenic profile of ALK-positive ALCL and circulating tumor DNA will be studied in this study. - At diagnosis (before starting treatment): - Cycle 2 Day 1 (before starting cycle 2 treatment): - At the end of treatment evaluation: 40 patients treated with 6 cycles of CHOEP every 3 weeks and 1 lumbar puncture at diagnosis with intrathecal prophylaxis with methotrexate will be included prospectively. During a 2-year period, relapses / progressions and patient deaths will be monitored for the calculation of the incidence of relapse / progression, progression free survival (PFS) and overall survival (OS). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02561273 -
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
| Recruiting |
NCT03505554 -
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
|
Phase 2 | |
| Completed |
NCT01979536 -
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03113500 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06176690 -
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05978141 -
A Registry for People With T-cell Lymphoma
|
||
| Withdrawn |
NCT02729961 -
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03719898 -
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04925609 -
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02419287 -
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
|
Phase 2 | |
| Completed |
NCT03493451 -
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
|
Phase 2 |